Article Data

  • Views 256
  • Dowloads 144

Original Research

Open Access

The association of AR-V7 with resistance to Abiraterone in metastatic castration-resistant prostate cancer

  • Shuo Wang1,†
  • Yudong Cao1,†
  • Xingxing Tang2
  • Xiao Yang1
  • Jinchao Ma1
  • Ziyi Yu1
  • Yong Yang1
  • Peng Du1,*,

1Department of Urology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of education/Beijing), Peking University Cancer Hospital and Institute, 100142 Beijing, China

2Department of Urology, Peking University First Hospital and Institute of Urology, Peking University, 100034 Beijing, China

DOI: 10.31083/j.jomh1803061 Vol.18,Issue 3,March 2022 pp.1-8

Submitted: 20 October 2021 Accepted: 01 December 2021

Published: 31 March 2022

*Corresponding Author(s): Peng Du E-mail:

† These authors contributed equally.


Background: This paper sought to investigate the association between androgen receptor splice variant 7 (AR-V7) status in circulating tumors cells (CTCs) and resistance to abiraterone (Abi) and docetaxel (Doc) in men with metastatic castration-resistant prostate cancer (mCRPC). Methods: This was a prospective clinical study, newly confirmed mCRPC patients who were randomized going to receive Abi or Doc with age ≥18 years were enrolled to detect the AR-V7 mRNA in CTCs. The association of AR-V7 status with Gleason Score, prostate specific antigen response rate (PSA RR), hormone-sensitive duration time (HSDT), time-to event outcomes, including PSA progression-free survival (PFS), clinical PFS, radiographic PFS and cancer-specific survival (CSS) was examined. Results: 139 patients with mCPRC were enrolled; 67 received Abi and 72 received Doc. The proportion of AR-V7-positive patients was 35.8% in Abi-treated patients and 34.7% in Doc-treated patients. Our results were as follows: (1) among men receiving Abi, AR-V7-positive patients had a higher Gleason Score (8.34 ± 1.03 vs. 7.29 ± 0.76, p = 0.012) and lower PSA RR (20.8% vs. 65.1%, p = 0.001) compared with AR-V7-negative patients; in a multivariable COX model, AR-V7 positivity was an independent risk factor for shorter PSA PFS (p = 0.012), clinical PFS (p = 0.036) and radiographic PFS (p = 0.028); (2) among men receiving Doc, AR-V7-positive patients also had a higher Gleason Score compared with AR-V7-negative patients (8.86 ± 0.66 vs. 7.57 ± 0.94, p < 0.0001), but no differences in PSA RR, PSA PFS, clinical PFS, radiographic PFS or CSS were observed; (3) among AR-V7-positive patients, men receiving Abi had lower a PSA RR compared with men receiving Doc (20.8% vs. 48%, p = 0.046); in a multivariable COX model, Abi was an independent risk factor for shorter PSA PFS (p = 0.040) and clinical PFS (p = 0.046); (4) among AR-V7-negative patients, there were no differences in PSA RR, PSA PFS, clinical PFS, radiographic PFS or CSS between Abi- and Doc-treated patients. Conclusion: AR-V7-positive patients commonly have a higher Gleason Score than AR-V7 negative patients, and AR-V7 positivity is strongly associated with Abi resistance in mCRPC but is not associated with the effectiveness of Doc.


Castration-resistant prostate cancer; Androgen receptor splice variant 7; Abiraterone; Docetaxel

Cite and Share

Shuo Wang,Yudong Cao,Xingxing Tang,Xiao Yang,Jinchao Ma,Ziyi Yu,Yong Yang,Peng Du. The association of AR-V7 with resistance to Abiraterone in metastatic castration-resistant prostate cancer. Journal of Men's Health. 2022. 18(3);1-8.


[1] Eisenberger MA, Walsh PC. Early Androgen Deprivation for Prostate Cancer? New England Journal of Medicine. 1999; 341: 1837–1838.

[2] Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology. 2012; 13: 983–992.

[3] Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus plus pre-dinisone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall sur-vival analysis of a randomized, double-blind, placebo-controlled phase 3 study. The Lancet Oncology. 2015; 16: 152–160.

[4] Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plust pred-nisone for advance prostate cancer. The New England Journal of Medicine. 2004; 351: 1502–1512.

[5] Toren PJ, Kim S, Pham S, Mangalji A, Adomat H, Guns EST, et al. Anticancer Activity of a Novel Selective CYP17a1 In-hibitor in Preclinical Models of Castrate-Resistant Prostate Can-cer. Molecular Cancer Therapeutics. 2015; 14: 59–69.

[6] Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and Resistance to Enzalutamide and Abi-raterone in Prostate Cancer. The New England Journal of Medicine. 2014; 371: 1028–1038.

[7] Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistance prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clinical Cancer Research. 2011; 17: 5913–5925.

[8] Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Research. 2009; 69: 16–22.

[9] Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tan-nahill C, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Research. 2012; 72: 3457–3462.

[10] Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. Journal of the National Cancer Institute. 2000; 92: 205–216.

[11] Ma Y, Luk A, Young FP, Lynch D, Chua W, Balakrishnar B, et al. Droplet digital PCR based androgen receptor variant 7 (AR-V7) detection from prostate cancer patients blood biopsies. International Journal of Molecular Sciences. 2016; 17: 1264–1275.

[12] Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Car-ducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology. 2008; 26: 1148–1159.

[13] Bastos DA, Antonarakis ES. CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate can-cer. Expert Review of Molecular Diagnostics. 2018; 18: 155–163.

[14] Hörnberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Wid-mark A, et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS ONE. 2011; 6: e19059.

[15] Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nature Reviews. Cancer. 2004; 4: 253–265.

[16] Zhu M, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kypri-anou N. Tubulin-targeting chemotherapy impairs androgen re-ceptor activity in prostate cancer. Cancer Research. 2010; 70: 7992–8002.

[17] Fitzpatrick JM, de Wit R. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. European Urology. 2014; 65: 1198–1204.

[18] van Soest RJ, van Royen ME, de Morrée ES, Moll JM, Teubel W, Wiemer EAC, et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. European Journal of Cancer. 2013; 49: 3821–3830.

[19] Nadal R, Zhang Z, Rahman H, Schweizer MT, Denmeade SR, Paller CJ, et al. Clinical activity of enzalutamide in docetaxel-naive and docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Prostate. 2014; 74: 1560–1568.

[20] Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, et al. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology. 2015; 1: 582–591.

[21] Thadani-Mulero M, Portella L, Sun S, Sung M, Matov A, Ves-sella RL, et al. Androgen receptor splice variants determine tax-ane sensitivity in prostate cancer. Cancer Research. 2014; 74: 2270–2282.

[22] Antonarakis ES, Lu C, Chen Y, Luber B, Wang H, Nakazawa M, et al. AR splice variant 7 (AR-V7) and response to tax-anes in men with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2015; 33: 138–138.

[23] Romanel A, Gasi Tandefelt D, Conteduca V, Jayaram A, Casir-aghi N, Wetterskog D, et al. Plasma AR and abiraterone-resistant prostate cancer. Science Translational Medicine. 2015; 7: 312re10.

[24] Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KAT, Dehm SM. Androgen receptor splice variants mediate enzalutamide re-sistance in castration-resistant prostate cancer cell lines. Cancer Research. 2013; 73: 483–489.

[25] Armstrong AJ, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, et al. Prospective Multicenter Study of Circu-lating Tumor Cell AR-V7 and Taxane Versus Hormonal Treat-ment Outcomes in Metastatic Castration-Resistant Prostate Can-cer. JCO Precision Oncology. 2020; 4: PO.20.00200.

[26] Markowski MC, Frick KD, Eshleman JR, Luo J, Antonarakis ES. Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide. Prostate. 2016; 76: 1484–1490.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Directory of Open Access Journals (DOAJ) DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.

SCImago The SCImago Journal & Country Rank is a publicly available portal that includes the journals and country scientific indicators developed from the information contained in the Scopus® database (Elsevier B.V.)

Publication Forum - JUFO (Federation of Finnish Learned Societies) Publication Forum is a classification of publication channels created by the Finnish scientific community to support the quality assessment of academic research.

Scopus CiteScore 0.7 (2021) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Norwegian Register for Scientific Journals, Series and Publishers Search for publication channels (journals, series and publishers) in the Norwegian Register for Scientific Journals, Series and Publishers to see if they are considered as scientific. (

Submission Turnaround Time